登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C22H38O5
化学文摘社编号:
分子量:
382.53
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
InChI
1S/C22H38O5/c1-4-5-14-22(2,26)15-10-12-18-17(19(23)16-20(18)24)11-8-6-7-9-13-21(25)27-3/h10,12,17-18,20,24,26H,4-9,11,13-16H2,1-3H3/b12-10+/t17-,18-,20-,22?/m1/s1
SMILES string
CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC
InChI key
OJLOPKGSLYJEMD-URPKTTJQSA-N
grade
pharmaceutical primary standard
API family
misoprostol
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
−20°C
Gene Information
human ... PTGER3(5733)
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Misoprostol for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Biochem/physiol Actions
PGE 1 类似物前体药物，迅速去酯化为活性“米索前列醇酸”。广泛的治疗作用，包括预防 NSAID 诱导的胃溃疡、调节免疫级联反应、抑制血小板活化因子（PAF）、治疗乙醇和扑热息痛诱导的肝毒性和肝炎以及刺激损伤后的软骨修复。
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral - Repr. 1B
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
监管及禁止进口产品
此项目有
Christina S Chu et al.
Journal of the Royal Society of Medicine, 105(8), 336-347 (2012-08-22)
This article describes and critically appraises clinical trials assessing misoprostol effectiveness in preventing primary postpartum haemorrhage (PPH) in home and community settings in low- and middle-income countries. Of 172 identified studies of misoprostol use in labour only six fulfilled the
V A Hundley et al.
BJOG : an international journal of obstetrics and gynaecology, 120(3), 277-285 (2012-11-30)
Using misoprostol to prevent postpartum haemorrhage (PPH) in home-birth settings remains controversial. To review the safety and effectiveness of oral misoprostol in preventing PPH in home-birth settings. The Cochrane Library, PubMed, and POPLINE were searched for articles published until 31
Jeanine F Carbone et al.
Obstetrics and gynecology, 121(2 Pt 1), 247-252 (2013-01-11)
To test the hypothesis that use of the Foley bulb plus vaginal misoprostol will result in shorter induction-to-delivery time compared with vaginal misoprostol alone. We randomized 123 women undergoing induction of labor with singleton pregnancies at 24 weeks of gestation
J Hua et al.
BJOG : an international journal of obstetrics and gynaecology, 120(5), 531-540 (2013-01-22)
The efficacy of misoprostol versus oxytocin for reducing blood loss during caesarean section remains unclear. To conduct a meta-analysis comparing the efficacy of misoprostol with that of oxytocin in reducing blood loss during caesarean section. We searched MEDLINE, Embase, the
N P Polyzos et al.
Human reproduction update, 18(4), 393-404 (2012-05-01)
Although several randomized controlled trials (RCTs) have examined the effect of misoprostol prior to hysteroscopy for cervical dilatation, no solid conclusion has been reached. We therefore set out to perform a meta-analysis of RCTs. We searched MEDLINE, the ISI Web
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持